Key result
Bosentan improves symptoms, exercise capacity, hemodynamics, and clinical outcomes in severe pulmonary hypertension.
Why the study?
Does bosentan improve symptoms and outcomes in patients with severe pulmonary hypertension?
Does bosentan improve symptoms and outcomes in patients with severe pulmonary hypertension?
Bosentan is an effective oral dual endothelin receptor antagonist that improves clinical, hemodynamic, and echocardiographic parameters in patients with severe pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
May support bosentan consideration in severe PH; leaves open randomized confirmation of outcome benefits.
Endothelin, a peptide produced primarily by vascular endothelial cells, was discovered in 1980 and it was characterized as a powerful vasoconstrictor and mitogen for smooth muscle. Endothelin binds to two types of receptors, ETA and ETB. Activation of ETA and ETB receptors on smooth muscle cells mediates the vasoconstrictive and mitogenic effects of endothelin. In patients with pulmonary hypertension, endothelin plasma levels are elevated and the increase is correlated with right atrial pressure, pulmonary artery oxygen saturation and pulmonary vascular resistance. Bosentan is an oral active dual ETA and ETBreceptor antagonist. Bosentan therapy has improved symptoms, exercise capacity, hemodynamics, echocardiographic parameters and the outcome of patients with severe pulmonary hypertension. This review is focus on the role of bosentan therapy in pulmonary hypertension and the review of current literature.
No takes yet. Share an insight, caveat, or question.
A 2002 study conducted a review in Pulmonary Arterial Hypertension. Bosentan was evaluated. Bosentan therapy improves symptoms, exercise capacity, hemodynamics, echocardiographic parameters, and outcomes in patients with severe pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: